Astrazeneca Pharma India Ltd
NSE: ASTRAZEN BSE: 506820
₹5957
+6.50 (0.11%)
Thu, 22 Oct 2026, 07:44 pm
Market Cap (in Cr)14717.5
PE Ratio87.80
Dividend0.61
Health Technology
Pharmaceuticals: Major
24.5KAstrazeneca Pharma India Financials
| Particulars | Mar 2006 | Mar 2007 | Mar 2008 | Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 2.25B | 2.70B | 3.04B | 3.54B | 3.97B | 4.75B | 5.46B | 3.90B | 4.74B | 4.69B | 5.64B | 5.44B | 5.71B | 7.28B | 8.32B | 8.09B | 8.06B | 10.03B | 12.96B | 17.16B |
| Gross profit | 972.85M | 744.81M | 1.45B | 2.46B | 1.81B | 2.86B | 1.87B | 403.19M | 1.03B | 734.05M | 1.49B | 1.51B | 1.66B | 2.35B | 2.75B | 2.59B | 2.31B | 3.55B | 4.32B | 4.43B |
| Operating expenses (excl. COGS) | -367.42M | -58.10M | -611.13M | -1.41B | -973.07M | -2.10B | -1.49B | -1.22B | -1.30B | -1.48B | -1.50B | -1.29B | -1.31B | -1.78B | -1.71B | -1.46B | -1.60B | -2.04B | -2.60B | -2.25B |
| Selling/general/admin expenses, total | — | — | -577.27M | -1.38B | -969.00M | -2.06B | -1.47B | -1.16B | -1.25B | -1.44B | -1.46B | -1.20B | -1.30B | -1.74B | -1.68B | -1.43B | -1.58B | -2.01B | -2.57B | -2.18B |
| Research & development | -20.82M | -22.10M | -23.48M | -23.61M | -21.06M | -25.74M | -14.41M | 0 | — | — | — | — | — | — | -227.00M | -287.60M | -391.90M | -591.60M | -728.60M | -312.40M |
| Selling/general/admin expenses, other | — | — | -553.79M | -1.36B | -947.93M | -2.04B | -1.45B | -1.16B | -1.25B | -1.44B | -1.46B | -1.20B | -1.30B | -1.74B | -1.46B | -1.15B | -1.19B | -1.42B | -1.84B | -1.87B |
| Other operating expenses, total | -367.42M | -58.10M | -33.86M | -22.50M | -4.08M | -31.24M | -27.81M | -54.99M | -54.27M | -45.87M | -34.05M | -90.90M | -13.10M | -37.50M | -26.30M | -26.30M | -19.70M | -23.50M | -27.60M | -73.30M |
| Operating income | 562.78M | 664.61M | 843.44M | 1.06B | 835.39M | 759.11M | 372.71M | -807.94M | -233.20M | -746.92M | -6.87M | 216.20M | 341.90M | 569.30M | 1.03B | 1.13B | 714.30M | 1.51B | 1.72B | 2.18B |
| Non-operating income, total | 74.68M | 71.19M | 96.70M | 70.57M | 45.01M | 48.41M | -80.16M | 105.24M | 233.20M | 538.52M | 64.50M | 194.67M | 96.10M | 157.40M | 104.80M | 142.20M | 116.10M | -168.90M | 477.90M | -613.30M |
| Interest expense, net of interest capitalized | -544.97K | 0 | 0 | -48.63M | -1.37M | 0 | — | — | 0 | 0 | 0 | 0 | 0 | 0 | -11.40M | -10.90M | -9.50M | -6.30M | -12.00M | -14.60M |
| Interest capitalized | 0 | 0 | 0 | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-operating income, excl. interest expenses | 75.23M | 71.19M | 96.70M | 119.20M | 46.38M | 48.41M | 62.84M | 105.24M | 94.31M | 533.47M | 64.50M | 138.80M | 118.50M | 157.40M | 116.20M | 156.90M | 125.60M | 239.70M | 323.80M | 373.80M |
| Non-operating interest income | 33.84M | 52.50M | 88.31M | 105.59M | 35.81M | 46.10M | 48.22M | 25.97M | 41.95M | 44.30M | 57.86M | 59.90M | 113.40M | 153.70M | 122.30M | 89.30M | 114.80M | 231.20M | 325.70M | 315.60M |
| Miscellaneous non-operating expense | 41.38M | 18.70M | 8.38M | 13.61M | 10.57M | 2.31M | 14.62M | 79.27M | 52.36M | 489.18M | 6.64M | 78.90M | 5.10M | 3.70M | -6.10M | 67.60M | 10.80M | 8.50M | -1.90M | 58.20M |
| Unusual income/expense | — | — | — | — | — | — | -143.00M | — | 138.89M | 5.05M | — | 55.87M | -22.40M | 0 | 0 | -3.80M | 0 | -402.30M | 166.10M | -972.50M |
| Pretax income | 637.46M | 735.80M | 940.13M | 1.13B | 880.40M | 807.83M | 292.55M | -702.70M | 0 | -208.40M | 57.64M | 355.00M | 438.00M | 726.70M | 1.14B | 1.27B | 830.40M | 1.34B | 2.20B | 1.56B |
| Taxes | -219.04M | -248.33M | -325.55M | -388.76M | -304.23M | -294.53M | -94.90M | -192.62M | -5.09M | 0 | -5.05M | -154.50M | -178.90M | -182.20M | -417.60M | -337.90M | -214.40M | -348.10M | -580.30M | -406.20M |
| Non-controlling/minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| After tax other income/expense | 12.16M | -105.69K | 0 | 0 | — | -308.87K | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income before discontinued operations | 430.58M | 487.36M | 614.59M | 738.35M | 576.17M | 512.99M | 197.65M | -895.32M | -5.09M | -208.40M | 52.59M | 200.50M | 259.10M | 544.50M | 722.10M | 933.00M | 616.00M | 992.90M | 1.62B | 1.16B |
| Net income | 430.58M | 487.36M | 614.59M | 738.35M | 576.17M | 512.99M | 197.65M | -895.32M | -5.09M | -208.40M | 52.59M | 200.50M | 259.10M | 544.50M | 722.10M | 933.00M | 616.00M | 992.90M | 1.62B | 1.16B |
| Dilution adjustment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Preferred dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted net income available to common stockholders | 430.58M | 487.36M | 614.59M | 738.35M | 576.17M | 512.99M | 197.65M | -895.32M | -5.09M | -208.40M | 52.59M | 200.50M | 259.10M | 544.50M | 722.10M | 933.00M | 616.00M | 992.90M | 1.62B | 1.16B |
| Basic earnings per share (Basic EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Diluted earnings per share (Diluted EPS) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | 614.72M | 721.92M | 901.84M | 1.13B | 897.27M | 829.61M | 447.30M | -690.04M | -168.94M | -594.10M | 167.40M | 374.50M | 489.30M | 718.50M | 1.22B | 1.33B | 883.80M | 1.67B | 1.87B | 2.58B |
| EBIT | 562.78M | 664.61M | 843.44M | 1.06B | 836.50M | 759.11M | 373.92M | -812.82M | -270.19M | -746.92M | -6.87M | 216.20M | 341.90M | 569.30M | 1.03B | 1.13B | 714.30M | 1.51B | 1.72B | 2.18B |
| Total operating expenses | -1.67B | -2.03B | -2.19B | -2.49B | -3.13B | -3.99B | -5.08B | -4.71B | -4.97B | -5.44B | -5.64B | -5.22B | -5.37B | -6.71B | -7.28B | -6.96B | -7.34B | -8.52B | -11.24B | -14.99B |
| Prepaid expenses | 46.87M | 38.59M | 70.90M | 2.12B | 22.78M | 70.31M | — | — | — | — | 74.15M | 68.10M | 69.50M | 73.80M | 82.80M | 83.90M | 108.20M | 117.70M | 109.60M | 142.10M |
| Deferred income, current | — | — | — | — | — | — | — | — | 16.43M | 36.31M | 87.50M | 96.80M | 16.00M | 0 | — | 128.30M | 306.90M | 401.70M | 496.10M | 732.60M |
| Capital and operating lease obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 93.00M | 86.30M | 50.20M | 36.90M | 27.80M | 294.50M |
| Operating lease liabilities | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Deferred tax liabilities | 33.43M | 32.08M | 31.77M | 25.04M | 20.51M | 16.61M | 13.27M | — | — | — | — | 33.40M | 17.70M | 10.60M | 28.30M | 27.80M | 18.70M | 15.30M | 10.60M | 89.80M |
| Deferred income, non-current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | 90.00M |
| Minority interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in accrued expenses | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Common dividends paid | -247.33M | -99.02M | -297.67M | -371.48M | -373.88M | -249.32M | -249.60M | 89.10M | — | 0 | 0 | 0 | 0 | 0 | -30.10M | -50.00M | -50.00M | -200.00M | -400.00M | -600.00M |
| Preferred dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
